-

01:09:13 PM

AXIM Stock News

AXIM - Axim Biotechnologies Inc

12/21/21 9:00 AM

OTC : AXIM

covid-19

CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, announced today that the Centers for Disease

RHEA-AI

neutral

11/18/21 11:15 AM

OTC : AXIM

covid-19

AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and

RHEA-AI

neutral

11/16/21 9:00 AM

OTC : AXIM

partnershipcovid-19

AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare

RHEA-AI

neutral

11/09/21 9:00 AM

OTC : AXIM

covid-19

AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,”

RHEA-AI

neutral

11/02/21 9:00 AM

OTC : AXIM

managementclinical trial

AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has appointed Michael E. Stern, MS,

RHEA-AI

neutral

10/20/21 9:00 AM

OTC : AXIM

management

AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye

RHEA-AI

neutral

10/12/21 9:00 AM

OTC : AXIM

covid-19

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the development of the second

RHEA-AI

neutral

10/11/21 9:00 AM

OTC : AXIM

management

AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease

RHEA-AI

positive

10/05/21 9:00 AM

OTC : AXIM

management

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease

RHEA-AI

neutral

09/21/21 9:00 AM

OTC : AXIM

management

AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare

RHEA-AI

neutral